[Federal Register Volume 71, Number 110 (Thursday, June 8, 2006)]
[Notices]
[Page 33315]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E6-8917]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application

    Pursuant to section 1301.33(a) of Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on December 12, 2005, 
Mallinckrodt Inc., 3600 North Second Street, St. Louis, Missouri 63147, 
made application by renewal to the Drug Enforcement Administration 
(DEA) to be registered as a bulk manufacturer of the basic classes of 
controlled substances listed in Schedules I and II:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Codeine-N-oxide (9053).....................  I
Difenoxin (9168)...........................  I
Dihydromorphine (9145).....................  I
Morphine-N-oxide (9307)....................  I
Norlevorphanol (9634)......................  I
Normorphine (9313).........................  I
Tetrahydrocannabinols (7370)...............  I
Alfentanil (9737)..........................  II
Amphetamine (1100).........................  II
Ecgonine (9180)............................  II
Codeine (9050).............................  II
Dextropropoxyphene, bulk (9273)............  II
Dihydrocodeine (9120)......................  II
Diphenoxylate (9170).......................  II
Diprenorphine (9058).......................  II
Etorphine HCL (9059).......................  II
Fentanyl (9801)............................  II
Hydrocodone (9193).........................  II
Hydromorphone (9150).......................  II
Levo-alphacetylmethadol (9648).............  II
Levorphanol (9220).........................  II
Meperidine (9230)..........................  II
Methadone (9250)...........................  II
Methadone intermediate (9254)..............  II
Methamphetamine (1105).....................  II
Methylphenidate (1724).....................  II
Metopon (9260).............................  II
Morphine (9300)............................  II
Nabilone (7379)............................  II
Opium extracts (9610)......................  II
Opium fluid extract (9620).................  II
Opium tincture (9630)......................  II
Opium, granulated (9640)...................  II
Opium, powdered (9639).....................  II
Oxycodone (9143)...........................  II
Oxymorphone (9652).........................  II
Phenazocine (9715).........................  II
Remifentanil (9739)........................  II
Sufentanil (9740)..........................  II
Thebaine (9333)............................  II
------------------------------------------------------------------------

    The firm plans to manufacture the listed controlled substances for 
internal use and for sale to other companies.
    Any other such applicant and any person who is presently registered 
with DEA to manufacture such a substance may file comments or 
objections to the issuance of the proposed registration pursuant to 21 
CFR 1301.33(a).
    Any such written comments or objections being sent via regular mail 
may be addressed, in quintuplicate, to the Deputy Assistant 
Administrator, Office of Diversion Control, Drug Enforcement 
Administration, Washington, DC 20537, Attention: DEA Federal Register 
Representative, Liaison and Policy Section (ODL); or any being sent via 
express mail should be sent to DEA Headquarters, Attention: DEA Federal 
Register Representative/ODL, 2401 Jefferson-Davis Highway, Alexandria, 
Virginia 22301; and must be filed no later than August 7, 2006.

    Dated: June 1, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. E6-8917 Filed 6-7-06; 8:45 am]
BILLING CODE 4410-09-P